- Targets solid waste, wastewater, industrial odor, advanced wound-care and distinfectant markets
- Clyra Medical unit has applied its technology to the coronavirus pandemic with public sales of its disinfectant spray
- Flagship product CupriDyne Clean marketed to cannabis producers seeking odor elimination
- Working with US EPA to develop system to remove harmful 'forever chemicals' from drinking water
What BioLargo does:
The company, based in Westminster, California, has developed several innovative and patented products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds (VOC) elimination, and advanced wound care.
BioLargo operates four subsidiaries: Odor-No-More Inc, BioLargo Water Inc, BioLargo Engineering, Science & Technologies Inc (BLEST) and Clyra Medical Technologies Inc.
The Odor-No-More division’s main product is CupriDyne Clean Industrial Odor and VOC Eliminator, which is aimed at the solid waste/landfill/compost, wastewater, and oil & gas industries. The product eliminates odor-causing compounds rather than masking them.
The BioLargo Water division develops the Advanced Oxidation System (AOS), an industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than current technologies.
The BioLargo Engineering division piggybacks on BioLargo Water by offering consulting and engineering services for the water and wastewater treatment industries. It also conducts environmental and Occupational Safety and Health Administration workplace-safety compliance audits.
The engineering division, along with the Odor-No-More unit, is targeting cannabis companies to adopt the company's CupriDyne Clean product, which eliminates the strong, pungent odors and VOCs emitted during growing and production. BioLargo cites some 15,000 cannabis production sites in California as potential customers.
The Clyra Medical unit develops products and solutions to safely treat chronic wound infections and promote healing while reducing the need for antibiotics.
Clyra is advancing with its stem-therapy technology called SkinDisc that uses a patient’s own bone marrow and plasma to help heal chronic wounds. The division also has US Food and Drug Administration clearance to market its Clyra Wound Irrigation Solution product for cleansing, irrigating, and debriding dermal wounds and burns.
The subsidiary has also taken its wound-healing technology and applied it to the coronavirus (COVID-19) pandemic in the form disinfectant products, including Clyraguard personal spray, a hospital-grade, FDA-registered germicide that can be easily applied on the go without having to remove a mask. The spray has been proven to deliver 99.999% antimicrobial efficacy against viruses, bacteria and fungi and demonstrated complete inactivation of SARS-CoV-2, the virus that causes COVID-19.
How is it doing:
BioLargo posted third-quarter results on October 8 that showed a revenue jump of 60% year-over-year on the back of contributions from all four of its divisions and strong business development efforts.
For the quarter ended September 30, 2020, the company reported revenue of $650,000, compared to $418,000 in revenue a year earlier.
The company’s revenues for the nine months ended September 30 were roughly $1.6 million, a 20% jump compared to the $1.3 million in revenue it generated in the same nine-month period in 2019.
Significantly, the company's balance sheet was bolstered with $3,553,000 of debt converted to equity since December 31, 2019.
BioLargo also revealed that Clyra Medical Technologies, which has created disinfectants capable of completely inactivating the coronavirus, has now made one product, its Clyraguard disinfecting spray available to the public, as of early October.
Regarding its water operations, the company recently received a $350,000 infusion from Bookang Tech Co LTD (BKT), a leading wastewater treatment company in South Korea, under an international joint venture (JV) struck in March to manufacture and distribute CupriDyne Clean Industrial Odor and VOC Eliminator products there and in eight other Asian nations in the region.
The JV could be lucrative to BioLargo in the long run. The partnership must achieve minimum sales targets to maintain exclusive rights in the Asian markets, and an annual dividend of $2 million will be paid to BioLargo to secure exclusive rights in perpetuity.
Although the company’s Odor-No-More unit stands as its key revenue driver, BioLargo is further expanding its water and related engineering subsidiaries as demand grows among farmers needing sustainable wastewater filtration systems to governments seeking ways to remove harmful chemicals from the public water supply.
The water unit’s main product is the Advanced Oxidation System (AOS) that uses highly energized iodine molecules with cutting-edge filtration materials to destroy bacteria and dismantle soluble organic contaminants.
AOS is currently being studied in California to treat stormwater runoff and at the Sunworks Farm in Alberta as part of a commercial trial to manage and treat water and wastewater on the property where organic chicken, turkey, beef and pork products are produced. The trial is a first for BioLargo and the last step before full commercialization of AOS.
In addition, the water subsidiary has launched a pilot program for the treatment of poultry wastewater processing at a facility in Camrose, Alberta and is running another pilot for the treatment of microbrewery wastewater in Joshua Tree, California.
The company has also taken executive steps to advance AOS. It recently hired wastewater industry veteran Tonya Chandler as director of strategic marketing and business development and initiated a regulated crowdfunding operation to secure the necessary funding to launch its water-treatment technology into the $246 million poultry processing market.
Aside from agricultural uses, BioLargo's engineering division sees a huge potential in developing a new water treatment technology to solve a serious global drinking water contamination problem caused by man-made “forever chemicals.”
These chemicals, resistant to breaking down in the environment, are known as per and fluoroalkyl substances, or PFAS. They’ve been inked to cancers, liver damage, low birth weight and other health problems.
In July, its BLEST unit completed manufacturing of its first prototype unit of its patented BioLargo AEC (Aqueous Electrostatic Concentrator).
The prototype is being tested and will be installed on-site for its first field pilot in the coming months, where the technology will be vetted in tough field conditions for its ability to effectively and affordably eliminate PFAS contaminants from water.
BioLargo said the technology has already been proven in lab-scale studies to eliminate 99% of PFAS from water in continuous flow while consuming as low as $0.30 in electrical costs per 1,000 gallons treated, representing a significant and potential cost savings compared to incumbent PFAS solutions like reverse osmosis and carbon sequestration technologies.
- Public sales for Clyraguard disinfectant spray
- Increase sales, especially to licensed cannabis growers, of CurpriDyne Clean product
- Launch Phase II of EPA grant study of PFAS compounds in water
What the boss says:
BioLargo CEO Dennis Calvert lauded the group's medical subsidiary’s recent successes with the company’s fiscal third-quarter results
"With our subsidiary Clyra Medical Technologies having successfully executed the first phase of the Clyraguard product launch, this quarter set new records for BioLargo, and we expect the next quarter to be even stronger for the company and Clyraguard,” Calvert said in a statement.
“We have made a significant investment in building our supply chain capabilities, organizing our marketing team, and dedicated business development efforts, and we expect future periods to continue to improve."
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel